Risk factors
Medpace Holdings (MEDP) risk factors
Item 1A of every Medpace Holdings, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors38 risks1 new2 reworded
Clinical trial funding shortfalls can force Medpace to cover completion or wind-down costs ethically. CEO August J. Troendle increased his control to 19.0% of outstanding common stock.
Filed Feb 10, 2026 - FY2024 10-K risk factors37 risks
Clinical trial client concentration and contract termination risks dominate operations. Fixed-fee underpricing and cost overruns threaten profit margins. Global regulatory compliance and cyber security vulnerabilities present significant ongoing exposures.
Filed Feb 11, 2025